EPO and myelodysplastic syndrome: On the contrary, PLCβ1 is a negative regulator of erythropoiesis; MDS cells obtained from lower-risk MDS during EPO therapy specifically downregulate nuclear PLCβ1 expression and activate the PI3K/Akt/PLCγ1 pathway, thus resulting in apoptosis and a low proliferation rate of MDS cells [57,58].